Let less evasion mechanisms for tumor cells. Combinations of these targeted drugs are fascinating and future agent kinase inhibitors such as sunitinib or sorafenib and several mTOR inhibitors with other inhibitors ABT-492 WQ-3034 of growth factor receptor inhibitors, which are combined histone deacetylase inhibitors, proteasome, or cytostatic biotherapy embroidered l effectively advanced GEP NET. The advantage of this new combination therapies is their gr Specificity ere t for tumor cells and greater efficiency, with acceptable toxicity t and side effects combined. New combination therapies to extend the therapeutic spectrum GEP NET, bile duct cancer originate from epithelial intraor extrahepatic bile ducts. They were first described by Durand Fardel in 1840.
Extrahepatic type Haupt Chlich cancers with the confluence of the right and left L��berg Length, which represents 80% to 90%, and the nature of intrahepatic for the remaining 10% to 20% of all cancers of the biliary tract. Hilaire BTC as a specific unit was in the first period by Klatskin in 1965, so. Its designation as Klatskin tumors BTC were rare b Sartige tumors with only 3% of gastrointestinal tumors. However, interest BTC w Highest due to an increase in the incidence and mortality T particularly connected in intrahepatic BTC. BTC is notoriously difficult to diagnose and is usually t Harmful, because the sp Th clinical pr Presentation and the lack of effective non-surgical treatment methods. Surgical resection or liver transplantation is the only potentially curative possibilities Behandlungsm.
Unfortunately, most patients have unresectable disease presentation Pr And die within 12 months. Liver failure and recurrent septicemia secondary Re bili Re obstruction, also contribute to the high mortality. Overall survival is poor, with less than 5% of patients survive 5 years BTC, a rate that has not changed ge In recent years it 30th Similar to CTB, there are no standard chemotherapy for patients with advanced bladder cancer. Therefore, innovative medicines are ben strongly effective medical treatment of the bile duct and gallbladder cancers CONFIRMS. This review is an overview Selected perspective Hlten agents that are currently taken into account in the development or testing or for more efficiency, targeted treatment of BTC. In addition, we will discuss promising Ans PageSever that have not been tested in BTC or gallbladder cancer, but sp Tere evaluations mandate.
Antiangiogenic therapeutic strategies angiogenesis plays an r Central role in the growth and tumor progression and its consequences have been extensively studied and described in the literature for various types of cancer. In the 1970s the first Folkman J was to develop the concept of tumor growth angiogenesis h Depends and. Specific hypothesis that the blockage of blood flow to the tumor in order to be a promising strategy for the treatment of cancer Among the angiogenic factors / receptors so far described, the Vaskul Ren endothelial growth factor and VEGF-receptor family, including normal glycoproteins Secreted VEGF A, B, VEGF, VEGF-C, VEGF-D, VEGF-E, factors placenta growth factor and its YEARS ring receptors VEGFR 1 and VEGFR 2 play an r Fingers.